A new system using NMR technology for measurement of body composition in experimental animals

Folia Pharmacologica Japonica

Volumn 123, Issue 4, 2004, Pages 281-287

  Suzuki, Jun ^a   Furutoh, Kenichi ^b   Nishikibe, Masaru ^a  

^a BANYU PHARMACEUTICAL CO LTD   (Japan)

^b Bruker Optics Inc   (United States)

Author keywords

Body composition; Fat mass; Mouse; NMR; Obesity

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BODY COMPOSITION; BODY WEIGHT; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET RESTRICTION; EXPERIMENTAL MODEL; LIPID DIET; LIVER WEIGHT; MEASUREMENT; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; QUADRICEPS FEMORIS MUSCLE; REVIEW;

ADIPOSE TISSUE; ANIMALS; BODY COMPOSITION; DIETARY FATS; FASTING; LIPID METABOLISM; LIVER; MAGNETIC RESONANCE SPECTROSCOPY; MICE; OBESITY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REPRODUCIBILITY OF RESULTS; TRANSCRIPTION FACTORS;

EID: 1842736741     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.123.281     Document Type: Review

References (12)

1. Alonso LG, Maren TH. Effect of food restriction on body composition of hereditary obese mice. Am J Physiol. 1955;183:284-290.
2. Boissonneault GA, Hornshuh MJ, Simons JW, Romsos DR, Leveille GA. Oxygen consumption and body fat content of young lean and obese (OB/OB) mice. Proc Soc Exp Biol Med. 1978;157:402-406.
3. Jansson JO, Wallenius K, Wernstedt I, Ohlsson C, Dickson SL, Wallenius V. On the site and mechanism of action of the anti-obesity effects of interleukin-6. Growth Horm IGF Res. 2003;13:S28-32.
4. Wang Z, Pierson RN, Heymfield SB. The five-level model: a new approach to organizing body-composition research. Am J Clin Nutr. 1992;56:19-28.
5. Tinsley FC, Taicher GZ, Heiman ML. Novel NMR technology provides quick and precise body composition measurement of live mice. presented at NAASO 2001, Quebec City, October 2001.
6. Comizio R, Pietrobelli A, Tan YX, et al. Total body lipid and triglyceride response to body composition models. Am J Physiol. 1998;274:E860-866.
7. Helge JW, Fraser AM, Kriketos AD, et al. Interrelationships between muscle fibre type, substrate oxidation and body fat. Int J Obes Relat Metab Disord. 1999;23:986-991.
8. Svenningsen A, Bonnevie-Nielsen V. Effects of fasting on beta-cell function, body fat, islet volume, and total pancreatic insulin content. Metabolism. 1984;33:612-616.
9. Mynatt RL, Stephens JM. Regulation of PPAR-gamma and obesity by agouti/melanocortin signaling in adipocytes. Ann N Y Acad Sci. 2003;994:141-146.
10. Liang G, Yang J, Horton JD, Hammer RE, Goldstein JL, Brown MS. Diminished hepatic response to fasting/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c. J Biol Chem. 2002;277:9520-9528.
11. Watkins SM, Reifsnyder PR, Pan HJ, German JB, Leiter EH. Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone. J Lipid Res. 2002;43:1809-1817.
12. Bedoucha M, Atzpodien E, Boelsterli UA. Diabetic KKAy mice exhibit increased hepatic PPARgamma 1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J Hepatol. 2001;35:17-23.